Enhancing the in vitro anti-cancer efficacy of artesunate by loading into poly-d,l-lactide-co-glycolide (PLGA) nanoparticles

Archives of Pharmacal Research

Volumn 38, Issue 5, 2015, Pages 716-724

  Nguyen, Hanh Thuy ^a   Tran, Tuan Hiep ^b   Kim, Jong Oh ^b   Yong, Chul Soon ^b   Nguyen, Chien Ngoc ^a  

^a HANOI UNIVERSITY OF PHARMACY   (Viet Nam)

^b Yeungnam University   (South Korea)

Author keywords

Anti cancer; Artesunate; Nanoparticles; Oil water emulsion evaporation; PLGA

Indexed keywords

ANTINEOPLASTIC AGENT; ARTEMISININ DERIVATIVE; ARTESUNATE; LACTIC ACID; NANOPARTICLE; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; HUMAN; MCF 7 CELL LINE; METABOLISM; PARTICLE SIZE; PHYSIOLOGY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ARTEMISININS; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LACTIC ACID; MCF-7 CELLS; NANOPARTICLES; PARTICLE SIZE; POLYGLYCOLIC ACID; TREATMENT OUTCOME;

EID: 84939874157     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-014-0424-3     Document Type: Article

References (23)

1. Acharya, S., and S.K. Sahoo. 2011. PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Advanced Drug Delivery Reviews 63: 170-183.
2. Chadha, R., S. Gupta, and N. Pathak. 2012. Artesunate-loaded chitosan/lecithin nanoparticles: Preparation, characterization, and in vivo studies. Drug Development and Industrial Pharmacy 38: 1538-1546.
3. Chen, Y., X. Lin, H. Park, and R. Greever. 2009. Study of artemisinin nanocapsules as anticancer drug delivery systems. Nanomedicine: Nanotechnology, Biology and Medicine 5: 316-322.
4. Chittasupho, C., S.-X. Xie, A. Baoum, T. Yakovleva, T.J. Siahaan, and C.J. Berkland. 2009. ICAM-1 targeting of doxorubicin-loaded PLGA nanoparticles to lung epithelial cells. European Journal of Pharmaceutical Sciences 37: 141-150.
5. Danhier, F., N. Lecouturier, B. Vroman, C. Jérôme, J. Marchand-Brynaert, O. Feron, and V. Préat. 2009. Paclitaxel-loaded PEGylated PLGA-based nanoparticles: In vitro and in vivo evaluation. Journal of Controlled Release 133: 11-17.
6. Efferth, T. 2007. Willmar Schwabe Award 2006: Antiplasmodial and antitumor activity of artemisinin-from bench to bedside. Planta Medica 73: 299-309.
7. Fredenberg, S., M. Wahlgren, M. Reslow, and A. Axelsson. 2011. The mechanisms of drug release in poly(lactic-co-glycolic acid)-based drug delivery systems - A review. International Journal of Pharmaceutics 415: 34-52.
8. Gabriels, M., and J. Plaizier-Vercammen. 2003. Physical and chemical evaluation of liposomes, containing artesunate. Journal of Pharmaceutical and Biomedical Analysis 31: 655-667.
9. Jain, R.A. 2000. The manufacturing techniques of various drug loaded biodegradable poly (poly-d, l-lactide-co-glycolide)(PLGA) devices. Biomaterials 21: 2475-2490.
10. Jin, C., L. Bai, H. Wu, W. Song, G. Guo, and K. Dou. 2009. Cytotoxicity of paclitaxel incorporated in PLGA nanoparticles on hypoxic human tumor cells. Pharmaceutical Research 26(7): 1776-1784.
11. Kumari, A., S.K. Yadav, and S.C. Yadav. 2010. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids and Surfaces B: Biointerfaces 75: 1-18.
12. Kwon, H.-Y., J.-Y. Lee, S.-W. Choi, Y. Jang, and J.-H. Kim. 2001. Preparation of PLGA nanoparticles containing estrogen by emulsification-diffusion method. Colloids and Surfaces A: Physicochemical and Engineering Aspects 182: 123-130.
13. Mainardes, R.M., and R.C. Evangelista. 2005. PLGA nanoparticles containing praziquantel: effect of formulation variables on size distribution. International Journal of Pharmaceutics 290: 137-144.
14. Pradhan, R., B.K. Poudel, T. Ramasamy, H.-G. Choi, C.S. Yong, and J.O. Kim. 2013. Docetaxel-loaded polylactic acid-co-glycolic acid nanoparticles: Formulation, physicochemical characterization and cytotoxicity studies. Journal of Nanoscience and Nanotechnology 13: 5948-5956.
15. Sahana, D., G. Mittal, V. Bhardwaj, and M. Kumar. 2008. PLGA nanoparticles for oral delivery of hydrophobic drugs: Influence of organic solvent on nanoparticle formation and release behavior in vitro and in vivo using estradiol as a model drug. Journal of Pharmaceutical Sciences 97: 1530-1542.
16. Tran, T.H., T. Ramasamy, H.J. Cho, Y.I. Kim, B.K. Poudel, H.-G. Choi, C.S. Yong, and J.O. Kim. 2014a. Formulation and optimization of raloxifene-loaded solid lipid nanoparticles to enhance oral bioavailability. Journal of Nanoscience and Nanotechnology 14(7): 4820-4831.
17. Tran, T. H., Ramasamy, T., Truong, D. H., Shin, B. S., Choi, H.-G., Yong, C. S., and Kim, J. O. 2014b. Development of vorinostat-loaded solid lipid nanoparticles to enhance pharmacokinetics and efficacy against multidrug resistant cancer cells. Pharmaceutical Research. doi: 10.1007/s11095-014-1300-z.
18. Woerdenbag, H.J., T.A. Moskal, N. Pras, T.M. Malingré, F.S. El-Feraly, H.H. Kampinga, and A.W. Konings. 1993. Cytotoxicity of artemisinin-related endoperoxides to Ehrlich ascites tumor cells. Journal of Natural Products 56: 849-856.
19. Xiao, X.-C., and Z.-G. Hong. 2010. Firstborn microcrystallization method to prepare nanocapsules containing artesunate. International Journal of Nanomedicine 5: 483.
20. Xu, Q., Z.-X. Li, H.-Q. Peng, Z.-W. Sun, R.-L. Cheng, Z.-M. Ye, and W.-X. Li. 2011. Artesunate inhibits growth and induces apoptosis in human osteosarcoma HOS cell line in vitro and in vivo. Journal of Zhejiang University SCIENCE B 12: 247-255.
21. Yallapu, M.M., B.K. Gupta, M. Jaggi, and S.C. Chauhan. 2010. Fabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells. Journal of Colloid and Interface Science 351: 19-29.
22. Zhang, Y.J., B. Gallis, M. Taya, S. Wang, R.J. Ho, and T. Sasaki. 2013. pH-responsive artemisinin derivatives and lipid nanoparticle formulations inhibit growth of breast cancer cells in vitro and induce down-regulation of HER family members. PLoS ONE 8: 14.
23. Zhou, X., W.J. Sun, W.M. Wang, K. Chen, J.H. Zheng, M.D. Lu, P.H. Li, and Z.Q. Zheng. 2013. Artesunate inhibits the growth of gastric cancer cells through the mechanism of promoting oncosis both in vitro and in vivo. Anti-Cancer Drugs 24: 920-927.